Skip to main content
. Author manuscript; available in PMC: 2010 Aug 10.
Published in final edited form as: J Med Chem. 2007 Aug 16;50(18):4493–4500. doi: 10.1021/jm070569b

Table II.

IC50 data for growth inhibition of cancer cells by doxorubicin and doxazolidine from the Developmental Therapeutics Program at the National Cancer Institute. Cells were treated with drug for 48 h.

log IC50 (M)
Cell Line Cancer Type Doxorubicina Doxazolidineb
HL-60(TB) Leukemia −7.23 −9.48
NCI-H460 NSCLC −8.22 < −9.68
HCT-116 Colon −7.15 −8.25
SF-268 CNS −7.04 −8.58
UACC-257 Melanoma −6.68 < −8.82
IGROV1 Ovarian −6.96 < −8.86
RXF 393 Renal −6.75 < −9.01
DU-145 Prostate −6.96 −8.50
MCF-7/ADR Breast −4.88 < −7.73
Mean −6.87 < −8.77c
a

Average of 1837 determinations with log maximum concentration (M) = −4.6.

b

Average of 2 determinations (RXF 393 data are from 1 determination) with log maximum concentration (M) = −6.0.

c

p<0.00001 in comparison with doxorubicin.